| Literature DB >> 31936777 |
Ravikanth Nanduri1, Takashi Furusawa1, Michael Bustin1.
Abstract
Chromatin plays a key role in regulating gene expression programs necessary for the orderly progress of development and for preventing changes in cell identity that can lead to disease. The high mobility group N (HMGN) is a family of nucleosome binding proteins that preferentially binds to chromatin regulatory sites including enhancers and promoters. HMGN proteins are ubiquitously expressed in all vertebrate cells potentially affecting chromatin function and epigenetic regulation in multiple cell types. Here, we review studies aimed at elucidating the biological function of HMGN proteins, focusing on their possible role in vertebrate development and the etiology of disease. The data indicate that changes in HMGN levels lead to cell type-specific phenotypes, suggesting that HMGN optimize epigenetic processes necessary for maintaining cell identity and for proper execution of specific cellular functions. This manuscript contains tables that can be used as a comprehensive resource for all the English written manuscripts describing research aimed at elucidating the biological function of the HMGN protein family.Entities:
Keywords: HMGN proteins; chromatin; development; epigenetics; gene regulation
Year: 2020 PMID: 31936777 PMCID: PMC7013550 DOI: 10.3390/ijms21020449
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Genetically modified high mobility group N (HMGN) mice *.
| Gene | Modification | References |
|---|---|---|
|
| Knockout | Birger, Y. et al., 2003 |
|
| Knockout | Deng, T. et al., 2015 |
|
| Knockout | Gao, X.L. et al., 2019 |
|
| Knockout | Ueda, T. et al., 2009 |
|
| Knockout | Ciappio, E.D. et al., 2014 |
|
| Knockout | Deng, T. et al., 2015 |
| Human | Transgenic | Bustin, M. et al., 1995 |
| Human | Transgenic | Kugler, J. et al., 2017 |
|
| Transgenic | Furusawa, T. et al., 2016 |
* All mouse lines listed except the line denoted by # were generated in the author’s laboratory. Additional commercial resources for genetically altered mice may be available.
HMGN in Development. Studies on the role of HMGN proteins in development and differentiation published in the English language. Reference given as PubMed Identifier (PMID).
| HMGN | Species | Study Model | Summary | Reference (PMID) |
|---|---|---|---|---|
| HMGN1 | Mouse | Myoblast differentiation | Overexpression of human HMGN1 inhibited the differentiation of mouse C2C12 myoblast cells into myotubes | 8514795 |
| HMGN1 | Mouse | Transcription in MEFs | HMGN1 is a negative regulator of N-Cadherin gene. N-Cadherin was also higher in the early embryos of HMGN1 KO compared to WT | 16279949 |
| HMGN1 | Mouse | Cornea differentiation and maturation | In corneal epithelium of Hmgn1 KO mice, corneal differentiation, maturation and gene expression were affected. In the wildtype mice, HMGN1 is colocalized with p63 and p63 expression was absent in the central region of the Hmgn1 KO cornea | 16466397 |
| HMGN1 | Mouse | Chondrocyte differentiation | In developing limb bud, Hmgn1 expression is inversely correlated to Sox9 expression and it is down regulated during chondrogenesis | 16382150 |
| HMGN1 | Mouse | Myogenesis and adipogenesis | Myogenesis or adipogenesis were induced in Hmgn1 knock down (KD) NIH3T3 cell line by overexpressing MyoD or C/EBPalpha. | 16451822 |
| HMGN1 | Mouse | Digit formation | At E13.5 mouse autopod, interdigital expression of | 20034106 |
| HMGN1 | Mouse | embryonic stem cells (ESCs) | HMGN1 is strongly expressed in oocytes and throughout all preimplantation stages. Loss of HMGN1 reduces the DNase I hypersensitivity (DHS) at CpG island promoters in ES cells | 23775126 |
| HMGN1 | Human | Transgenic mice | HMGN1 is negative regulator for methyl CpG-binding protein 2. Hence, mice overexpressing HMGN1 displayed abnormalities in activity and anxiety and to social deficits | 22009741 |
| HMGN1 | Mouse | Down syndrome model mouse. | HMGN1 is overexpressed in Down syndrome and in all down syndrome model mice | 2140193 |
| 16635258 | ||||
| HMGN2 | Mouse | Kidney differentiation | During metanephric kidney development, HMGN2 expression is highly linked to induction and differentiation in kidney organogenesis | 11683498 |
| HMGN1 HMGN2 | Mouse | Myoblast differentiation | During myogenesis the level of | 1689723 |
| HMGN1 HMGN2 | Chicken | Erythroid cells | Erythroid cells from 5-day chicken embryos contain higher level of | 1993650 |
| HMGN1 HMGN2 | Rat Human | Osteoblast differentiation and monocyte differentiation | In both primary cultures of calvarial-derived rat osteoblasts and human leukemia HL-60 cells, HMGN1 and HMGN2 are preferentially expressed in the proliferating state, and the levels are down-regulated during differentiation. | 8496248 |
| HMGN1 HMGN2 | Mouse | Early embryonic development | HMGN1 and HMGN2 were detected throughout oogenesis and embryonic transcripts accumulate beyond the two-cell stage. Depletion of HMGNs in one-cell or two-cell mouse embryos delays subsequent progression. | 11133167 |
| HMGN1 HMGN2 | Xenopus | Early embryonic development | Depletion of | 14568106 |
| HMGN1 HMGN2 | Bovine | Maternal-zygotic transition | During bovine embryo early stage development, HMGN1 and HMGN2 are expressed in oocytes but are downregulated after fertilization and almost disappear by the 8-cell stage | 14960490 |
| HMGN1 HMGN2 | Mouse | Hair follicle cycle | 19303948 | |
| HMGN1 HMGN2 | Mouse | MEF, mouse behavior | Genome wide mapping of DHSs sites in MEFs from HMGN1 KO, HMGN2 KO and HMGN DKO revealed that loss of both, but not single HMGN variant leads to significant remodeling of DHS especially at enhancer regions | 26156321 |
| HMGN1 HMGN2 | Mouse | B lymphocyte | Loss of HMGN1 and HMGN2 proteins affect gene expression by modulating chromatin regulatory sites during activation of naïve B cells | 27112571 |
| HMGN1 HMGN2 | Mouse | Oligodendrocyte differentiation | Loss of HMGNs affect the expression of OLIG2 and OLIG1, thereby affecting oligodendrocyte development and nerve myelination, and mouse behavior | 27923998 |
| HMGN1 HMGN2 | Mouse | MEFs, induced pluripotent stem cells (iPSCs) | MEFs from Hmgn1/2 DKO mice showed enhanced rate of iPSCs induction by OSKM factors, and into neurons induced by ASCL1 | 30532006 |
| HMGN1 HMGN2 HMGN3 | Mouse | Eye development | HMGN1, HMGN2 and HMGN3 displayed dynamic and specific expression patterns during ocular development (E10.5, E13.5 and newborn) and adult eye | 18502697 |
| HMGN1 HMGN2 HMGN3 | Mouse | Astrocyte differentiation | Ectopic expression of either HMGN1, HMGN2 or HMGN3 in neural precursor cells (NPCs) or in late embryonic neocortex promoted the generation of astrocytes while knockdown suppressed astrocyte differentiation. | 25069414 |
| HMGN2 | Bovine | Early embryonic development | An in vitro fertilization study of bovine embryos revealed that embryos with enhanced levels of HMGN2 failed to develop into blastocyst due to the altered chromatin remodeling which might be caused by hyperacetylation of Histone H3 at lysine 14 residue | 17712799 |
| HMGN2 | Mouse | Tooth development | HMGN2 binds to Pitx2 and inhibits Pitx2 mediated Amelogenin expression during tooth development | 23975681 |
| HMGN2 | Mouse | Corticogenesis (Cerebral cortex development) | 31699896 | |
| HMGN3 | Xenopus | Anuran metamorphosis | 11921340 | |
| HMGN3 | Mouse | Retina | HMGN3 is highly expressed in glia cells and eye. HMGN3 binds to glycine transporter 1 (Glyt1) gene and upregulates its expression. | 15082770 |
| HMGN3 | Mouse | Pancreas (beta cells) | Loss of HMGN3 abrogates glucose stimulated insulin secretion and HMGN3 KO mice possess diabetic phenotype. HMGN3 along with PDX1regulates Glu2 gene | 19651901 |
| HMGN3 | Bovine | Early embryonic development | 19393058 | |
| HMGN3 | Mouse | Pancreas (alpha cells) | HMGN3 is highly expressed in pancreatic alpha cells, and that Hmgn3 KO mice displayed reduced glucagon levels in their blood | 19885867 |
| HMGN3 | Mouse | Decidualization | HMGN3 is highly expressed in decidua and decidualizing stromal cells, and also in the artificially stimulated decidualization | 26112184 |
| HMGN5 | Mouse | Placenta development | 19160411 | |
| HMGN5 | Mouse | Metabolomics | Metabolomic analysis of liver extracts and urine from | 24392144 |
| HMGN5 | Mouse | Heart development | Transgenic mice overexpressing HMGN5 (both ubiquitous or heart specific) are normal at birth but develop hypertrophic heart with large cardiomyocytes, deformed nuclei and disrupted lamina and die of cardiac malfunction | 25609380 |
HMGN in Disease. Studies on the role of HMGN proteins in different diseases published in English language. Reference given as PMID.
| HMGN | Study Model | Disease | Role/Function | Summary | Reference (PMID) |
|---|---|---|---|---|---|
| HMGN1 | Mice | Cancer | Immunoadjuvant | Augments antitumor immunity of alpha-fetoprotein expressing lentiviral vaccines in hepatocellular carcinoma mice | 31281528 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | Treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice | 30696484 |
| HMGN1 | Cell culture | Cancer | Immunoadjuvant | HMGN1 promotes dendritic cells (DC) recruitment through interacting with a Gαi protein-coupled receptor and activates DCs predominantly through triggering toll like receptor 4 (TLR4) | 29503123 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | Intratumoral delivery of HMGN1 and R848 along with cytoxan (TheraVac) eradicated large established CT26, Renca and EG7 tumors in mice | 29079801 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | Intratumoral injections cured mice harboring large established subcutaneous Hepa1-6 hepatomas | 28881713 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | HMGN1 contributes to antitumor immunity | 25205103 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | HMGN1 induced DC maturation via TLR4, recruitment of antigen presenting cells at sites of injection and promoted antigen-specific immune response upon co-administration with antigens | 22184635 |
| HMGN1 | Mice | Cancer | Immunoadjuvant | DNA(TA) encapsulated within peptide hydrogels encodes for a melanoma-specific gp100 antigen fused to the HMGN1 enhanced immunostimulatory effects in tumor mice model | 25890750 |
| HMGN1 | Mice | Cancer | Protumor activity | Down syndrome associated triplication of a 21q22 region contributes to B cell proliferation with increased risk of B cell acute lymphoblastic leukemia through HMGN1 overexpression | 24747640 |
| HMGN1 | Cell culture | Cancer | Protumor activity | High expression of HMGN1 in highly metastatic cells of MDA-MB-435 suggests the association of HMGN1 with metastasis of breast cancer cells | 16979889 |
| HMGN1 | Patient’s studies | Cancer | Protumor activity | Endoplasmic reticulum stress induces secretion of HMGN1 and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer | 27494867 |
| HMGN1 | Patient’s studies | Cancer | Protumor activity | High cytoplasmic expression of HMGN1 was associated with a high histological grade, high levels of tumor infiltering lymphocytes (TILs) in HER2-positive breast cancer tissues | 26445971 |
| HMGN1 | Patient’s studies | Cancer | Biomarker | Patients with high serum HMGN1 had a poorer overall survival after curative pneumonectomy in non-small cell lung cancer | 26113410 |
| HMGN1 | Cell culture | Cancer | Transcriptional regulator | HMGN1 and HMGN2 are synthesized throughout the S-phase and persists through the cell cycle in Burkitt’s lymphoma | 8670211 |
| HMGN1 | Mice | Cancer | Antitumor activity | Loss of HMGN1 accelerates the progression of N-nitrosodiethylamine-induced hepatocarcinogenesis | 24296759 |
| HMGN1 | Mice | Cancer | Antitumor activity | Loss of HMGN1 increases the tumorigenicity and sensitivity to Ionizing radiations | 16061652 |
| HMGN1 | Patient’s studies | Down Syndrome | Transcriptional regulator | Gene dosage studies in cultured cells and brain tissue samples obtained from Down syndrome patients suggest that HMGN1 as contributing factor in the etiology of Down syndrome | 1825298 |
| HMGN1 | Mice | Down Syndrome | Gene locus | HMGN1 maps to the 21q22.3 in humans, the region associated with the pathogenesis of Down syndrome, and to chromosome 16 in mice | 2140193 |
| HMGN1 | Mice | Down Syndrome | Transcriptional regulator | Overexpression of the HMGN1 (encoded on chr21q22) reiterates transcriptional changes seen with triplication of Down syndrome critical region on distal chromosome 21 | 30428356 |
| HMGN1 | Mice | Diabetic nephropathy | Transcriptional regulator | HMGN1 expression correlates with epithelial mesenchymal transition, renal fibrosis in diabetic nephropathy mice | 31203283 |
| HMGN1 | Mice | Diabetic nephropathy | Transcriptional regulator | Insulin growth factor 1 receptor inhibitor attenuates diabetic nephropathy by suppressing HMGN1-TLR4 pathway | 29384065 |
| HMGN1 | Rats | Amnesia | Biomarker | Increased HMGN1 phosphorylation by protein kinase CK2 decreases amnesia in aged rats | 14635996 |
| HMGN1 | Patient’s studies | Systemic sclerosis | Immunogen in autoimmunity | Autoantibodies against HMGN1 and HMGN2 were found in systemic sclerosis patients’ sera | 7869312 |
| HMGN1 | Patient’s studies | Drug induced lupus | Immunogen in autoimmunity | Autoantibodies against HMGN1 and HMGN2 were found in drug induced lupus patients | 7907477 |
| HMGN1 | Patient’s studies | Primary pulmonary hypertension | Immunogen in autoimmunity | Autoantibodies against HMGN1 were found in sera from primary pulmonary hypertension patients | 8918589 |
| HMGN1 | Mice | Immune Tolerance | TLR-4 agonist | HMGN1 induces innate immune tolerance in a TLR4 dependent Sirtuin-1 mediated deacetylation in human blood peripheral mononuclear cells | 29593748 |
| HMGN2 | Mice | Cancer | Antitumor activity | The tumor volumes in SaO2 and U2-OS osteocarcinoma subcutaneous nude mouse models treated with overexpressing HMGN2 lentivirus were significantly decreased | 25530340 |
| HMGN2 | Mice | Cancer | Antitumor activity | Overexpression of HMGN2 significantly decreased migration capacity, increased apoptosis of MCF7 breast cancer cells both in vitro and in vivo | 30655878 |
| HMGN2 | Cell culture | Cancer | Protumor activity | HMGN2 was increased in tumor cell line MDA-MB-468 and also in metastatic oral squamous cell carcinoma tissues | 29541221 |
| HMGN2 | Cell culture | Cancer | Antitumor activity | Isopentenyl pyrophosphate activated | 29401165 |
| HMGN2 | Cell culture | Cancer | Antitumor activity | Overexpression of HMGN2 in by lentivirus, inhibits the growth and migration of osteosarcoma cells | 25530340 |
| HMGN2 | Cell culture | Cancer | Signal transducer | Surface expressed of HMGN2 on leukemic B cells binds to autoantigen erythrocyte protein band 3 and contributes to initiation of autoimmune hemolytic anemia | 25156469 |
| HMGN2 | Cell culture | Cancer | Antitumor activity | Phytohemagglutinin activated CD8 T cells releases high level of HMGN2 and kill tumor cells | 25060707 |
| HMGN2 | Cell culture | Cancer | Protumor activity | Prolactin induced H1 disassociation mediated by HMGN2 induce STAT5 recruitment and breast cancer pathogenesis | 28035005 |
| HMGN2 | Patient studies | Cancer | Protumor activity | Expression of HMGN2 was higher in human leukemia cells with chronic myelogenic leukemia | 8528142 |
| HMGN2 | Cell culture | Cancer | Protumor activity | HDAC6 mediated deacetylation of HMGN2 enhances Stat5a transcriptional activity, thereby regulating prolactin-induced gene transcription and breast cancer growth | 27358110 |
| HMGN2 | Cell culture | Cancer | Biomarker | HMGN1 and HMGN2 are synthesized throughout the S-phase and persists through the cell cycle in Burkitt’s lymphoma | 8670211 |
| HMGN2 | Cell culture | Cancer | Antitumor activity | HMGN2 is a direct target of MicroRNA-23a which plays crucial role in epithelial mesenchymal transition (EMT) in lung cancer cells suggests its role | 23437179 |
| HMGN2 | Mice | Cancer | Antitumor activity | HMGN2 exerts inhibitory effect on tumors in human tongue carcinoma transplanted nude mice | 24665631 |
| HMGN2 | Mice | Cancer | Antitumor activity | HMGN2 treatment inhibited the growth, increased apoptosis of Tca8113 cells in vitro and in vivo | 24348831 |
| HMGN2 | Cell culture | Cancer | Antimicrobial activity | 31-aa peptide (F3) in the HMGN2 sequence homed to HL-60 and MDA-MB-435 tumors upon I.v. injection | 12032302 |
| HMGN2 | Patient studies | Cancer | Immunogen in autoimmunity | High throughput screening of autoantibodies in ovarian cancer ascitic fluids revealed HMGN2 as an antigen | 31428516 |
| HMGN2 | Cell culture | Infection | Transcriptional regulator | HMGN2 regulates the expression of antimicrobial peptides in Uropathogenic Escherichia coli J96-infected bladder epithelial cell monolayer | 29549670 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 displayed anti-bacterial and anti-biofilm activity against Escherichia coli K12 | 28471113 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 inhibits Pseudomonas aeruginosa internalization in A549 cells | 28408162 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 protects bladder epithelial cells from Klebsiella invasion | 21720014 |
| HMGN2 | Cell culture | Infection | Transcriptional regulator | Knockdown of HMGN2 affected the survival of non-tuberculosis mycobacteria in macrophage | 31596045 |
| HMGN2 | Cell culture | Infection | Transcriptional regulator | HMGN2 is a target of miR-155, which is downregulated in Klebsiella pneumoniae infection suggested the role in controlling infection | 27534887 |
| HMGN2 | Cell culture | Infection | Transcriptional regulator | Knockdown of HMGN2 increases the internalization of Klebsiella pneumoniae by respiratory epithelial cells | 27460641 |
| HMGN2 | Mice | Infection | Antimicrobial activity | HMGN2 is crucial for LPS induced expression of murine β-defensin-3 and -4 in mice | 21594618 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 is crucial for LPS induced expression of murine β-defensin-3 and -4 in A549 cells | 21518253 |
| HMGN2 | Mice | Infection | Antimicrobial activity | HMGN2 inhibits the invasion of Klebsiella pneumoniae into mouse lungs in vivo | 25760831 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 inhibited hepatitis B virus infection and replication in HepG2.2.15 cell line | 19150374 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 inhibited internalization of Klebsiella pneumoniae into cultured bladder epithelial cells | 21778192 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | N-terminal amino sequence was PKRKAEGDAK of HMGN2 is a novel antimicrobial peptide | 16204630 |
| HMGN2 | Cell culture | Infection | Antimicrobial activity | HMGN2 showed potent antimicrobial activity against E coli ML-35p, P aeruginosa ATCC 27853 | 16115376 |
| HMGN2 | Patient’s studies | Systemic lupus erythromatosus | Immunogen in autoimmunity | Autoantibodies against HMGN2 were found in systemic lupus erythromatosis (SLE) patients | 8037838 |
| HMGN2 | Patient’s studies | Systemic lupus erythromatosus | Immunogen in autoimmunity | Autoantibodies to HMGN2 were found in different autoimmune diseases and are more frequent in Systemic lupus erythromatosus | 8318042 |
| HMGN2 | Patient’s studies | Systemic lupus erythromatosus | Immunogen in autoimmunity | Autoantibodies to HMGN2 were present in serums from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD) | 6460317 |
| HMGN2 | Patient’s studies | Drug induced lupus | Immunogen in autoimmunity | Autoantibodies against HMGN1 and HMGN2 were found in drug induced lupus patients | 7907477 |
| HMGN2 | Patient’s studies | Juvenile Rheumatoid Arthritis | Immunogen in autoimmunity | Autoantibodies to HMGN2 were detected in ANA-positive patients with periarticular-onset Juvenile Rheumatoid Arthritis | 7517709 |
| HMGN2 | Patient’s studies | Juvenile Rheumatoid Arthritis | Immunogen in autoimmunity | Autoantibodies to HMGN2 were detected in patients with Juvenile Rheumatoid Arthritis | 1567496 |
| HMGN2 | Patient’s studies | Periodontitis | Biomarker | HMGN2 in saliva of periodontitis patients was higher especially with severe periodontitis | 28591948 |
| HMGN2 | Mice | Microcephaly | Transcriptional regulator | HMGN2 protects against Microcephaly by maintaining chromatin accessibility during corticogenesis | 31699896 |
| HMGN3 | Mice | Diabetes | Anti-diabetic | Hmgn3-/- mice which have a mild diabetic phenotype, with reduced glucagon levels in the blood | 19885867 |
| HMGN3 | Mice | Diabetes | Anti-diabetic | In mice, loss of HMGN3 blunt glucose-stimulated insulin secretion and have a diabetic phenotype. HMGN3 regulates Glut4 gene in pancreatic beta cells | 19651901 |
| HMGN4 | Patient’s studies | Cancer | Biomarker | Patients with high expression of HMGN4 have high grade tumors, shorter overall survival in hepatocellular carcinoma | 30272824 |
| HMGN4 | Mice | Cancer | Protumor activity | Mouse and human cells overexpressing HMGN4 displayed increased tumorigenicity in thyroid tumor mouse model | 28186538 |
| HMGN5 | Cell culture | Cancer | Protumor activity | microRNA-183-3p directly inhibits the expression of HMGN5 and prostate cancer progression | 31314587 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 expression was upregulated in pancreatic ductal adenocarcinoma tissues and cell lines. | 30128022 |
| HMGN5 | Cell culture | Cancer | Protumor activity | miR-488 inhibits cell growth and metastasis in renal cell carcinoma by abrogating HMGN5 expression | 29713189 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 expression was significantly upregulated in bladder transitional cell carcinoma tissues | 29509244 |
| HMGN5 | Cell culture | Cancer | Protumor activity | Silencing HMGN5 promotes chemosensitivity of human bladder cancer cells to cisplatin | 29163683 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 was significantly upregulated in esophageal squamous cell carcinoma cells. Silencing of HMGN5 significantly inhibited cell growth and induced cell apoptosis of ESCC cells | 28914995 |
| HMGN5 | Cell culture | Cancer | Protumor activity | microRNA-495 inhibits the proliferation and invasion and induces the apoptosis of osteosarcoma cells by inhibiting HMGN5 | 28627703 |
| HMGN5 | Cell culture | Cancer | Protumor activity | MicroRNA-140-5p expression enhances osteosarcoma chemoresistance by targeting HMGN5 and autophagy | 28341864 |
| HMGN5 | Cell culture | Cancer | Protumor activity | MicroRNA-409-3p decreases glioma cell invasion and proliferation by targeting HMGN5 | 28109076 |
| HMGN5 | Cell culture | Cancer | Protumor activity | microRNA-340 inhibits tumorigenic potential of prostate cancer cells by abrogating HMGN5 expression | 26394192 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 silencing enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas | 26315299 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 silencing suppresses the viability and invasion of human urothelial bladder cancer 5637 cells | 25796505 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 is over expressed in prostate cancer cells and activates MAPK and its expression is correlated with chemosensitivity | 25572120 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 is highly expressed in breast cancer cells and prompts proliferation and invasion | 25315189 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 silencing in cells exhibit increased apoptosis rate and decreased colonogenic survival in response to 2–8 Gy ionizing radiation | 25307178 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 was positively correlated with pathologic staging and TNM staging of osteosarcoma | 24687550 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 increases drug resistance in osteosarcoma cell lines U-2OS and MG63 through upregulating autophagy | 24664583 |
| HMGN5 | Cell culture | Cancer | Protumor activity | Silencing of HMGN5 induces apoptosis through the modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells | 22504871 |
| HMGN5 | Cell culture | Cancer | Protumor activity | Knockdown of HMGN5 slowed down the cell cycle at the G0/G1 phase in human lung cancer cell lines A549 and H1299 | 22994738 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 silencing inhibits the growth and invasion of clear cell renal cell carcinoma cells and its expression is associated with tumor grade | 22420896 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 promotes the viability of bladder cancer cells through increased cell proliferation, invasion ability of metastatic bladder cancer cells through the upregulation of MMP-9 | 21695596 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 knockdown causes cell cycle arrest in human glioma U251 and U87 cells and it is highly expressed in high grade and low-grade tumor tissues | 21373965 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 knockdown causes cell cycle arrest in prostate cancer cell line DU145 | 20531280 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 knockdown inhibits proliferation and tumorigenicity of BGC823 and SGC7901 gastric cancer cell lines | 30854121 |
| HMGN5 | Cell culture | Cancer | Protumor activity | MicroRNA-186 suppresses the growth and metastasis of bladder cancer by targeting HMGN5 | 26290438 |
| HMGN5 | Cell culture | Cancer | Protumor activity | HMGN5 knockdown inhibits proliferation and tumorogenecity of BGC823 and SGC7901 gastric cancer cell lines | 30854121 |
| HMGN5 | Cell culture | Cancer | Protumor activity | MicroRNA-186 suppresses the growth and metastasis of bladder cancer by targeting HMGN5 | 26290438 |
Figure 1HMGN proteins in development and disease. Shown is a schematic illustration of the biological processes reported to be affected by members of the HMGN protein family. The center panel depicts a nucleosome complexed with two molecules of HMGN protein. The number shown below each panel is the PMID of an article that discusses a role of HMGN in a specific biological process. Not all the biological processes affected by HMGN are depicted. A comprehensive list of reference to articles on the biological functions of HMGN is presented in Table 2 and Table 3.